731 related articles for article (PubMed ID: 23994717)
1. The absence of indoleamine 2,3-dioxygenase expression protects against NMDA receptor-mediated excitotoxicity in mouse brain.
Mazarei G; Budac DP; Lu G; Lee H; Möller T; Leavitt BR
Exp Neurol; 2013 Nov; 249():144-8. PubMed ID: 23994717
[TBL] [Abstract][Full Text] [Related]
2. Age-dependent alterations of the kynurenine pathway in the YAC128 mouse model of Huntington disease.
Mazarei G; Budac DP; Lu G; Adomat H; Tomlinson Guns ES; Möller T; Leavitt BR
J Neurochem; 2013 Dec; 127(6):852-67. PubMed ID: 23786539
[TBL] [Abstract][Full Text] [Related]
3. Indoleamine 2,3 Dioxygenase as a Potential Therapeutic Target in Huntington's Disease.
Mazarei G; Leavitt BR
J Huntingtons Dis; 2015; 4(2):109-18. PubMed ID: 26397892
[TBL] [Abstract][Full Text] [Related]
4. Dramatic changes in oxidative tryptophan metabolism along the kynurenine pathway in experimental cerebral and noncerebral malaria.
Sanni LA; Thomas SR; Tattam BN; Moore DE; Chaudhri G; Stocker R; Hunt NH
Am J Pathol; 1998 Feb; 152(2):611-9. PubMed ID: 9466588
[TBL] [Abstract][Full Text] [Related]
5. Modulation of striatal quinolinate neurotoxicity by elevation of endogenous brain kynurenic acid.
Harris CA; Miranda AF; Tanguay JJ; Boegman RJ; Beninger RJ; Jhamandas K
Br J Pharmacol; 1998 May; 124(2):391-9. PubMed ID: 9641558
[TBL] [Abstract][Full Text] [Related]
6. The kynurenine pathway in neurodegenerative diseases: mechanistic and therapeutic considerations.
Tan L; Yu JT; Tan L
J Neurol Sci; 2012 Dec; 323(1-2):1-8. PubMed ID: 22939820
[TBL] [Abstract][Full Text] [Related]
7. Indoleamine 2,3-dioxygenase-2; a new enzyme in the kynurenine pathway.
Ball HJ; Yuasa HJ; Austin CJ; Weiser S; Hunt NH
Int J Biochem Cell Biol; 2009 Mar; 41(3):467-71. PubMed ID: 18282734
[TBL] [Abstract][Full Text] [Related]
8. Indoleamine 2,3-dioxygenase as a novel therapeutic target for Huntington's disease.
Boros FA; Klivényi P; Toldi J; Vécsei L
Expert Opin Ther Targets; 2019 Jan; 23(1):39-51. PubMed ID: 30449219
[TBL] [Abstract][Full Text] [Related]
9. Increased indoleamine 2,3-dioxygenase (IDO) activity and elevated serum levels of tryptophan catabolites in patients with chronic kidney disease: a possible link between chronic inflammation and uraemic symptoms.
Schefold JC; Zeden JP; Fotopoulou C; von Haehling S; Pschowski R; Hasper D; Volk HD; Schuett C; Reinke P
Nephrol Dial Transplant; 2009 Jun; 24(6):1901-8. PubMed ID: 19155537
[TBL] [Abstract][Full Text] [Related]
10. Effect of indoleamine dioxygenase-1 deficiency and kynurenine pathway inhibition on murine cerebral malaria.
Miu J; Ball HJ; Mellor AL; Hunt NH
Int J Parasitol; 2009 Feb; 39(3):363-70. PubMed ID: 19000912
[TBL] [Abstract][Full Text] [Related]
11. Characterization of indoleamine-2,3-dioxygenase 1, tryptophan-2,3-dioxygenase, and Ido1/Tdo2 knockout mice.
Aslamkhan AG; Xu Q; Loughlin A; Vu H; Pacchione S; Bhatt B; Garfinkel I; Styring TG; LaFranco-Scheuch L; Pearson K; Reynolds S; Li N; Zhou H; Miller JR; Solban N; Bass A; Glaab WE
Toxicol Appl Pharmacol; 2020 Nov; 406():115216. PubMed ID: 32871117
[TBL] [Abstract][Full Text] [Related]
12. Network beyond IDO in psychiatric disorders: revisiting neurodegeneration hypothesis.
Myint AM; Kim YK
Prog Neuropsychopharmacol Biol Psychiatry; 2014 Jan; 48():304-13. PubMed ID: 24184687
[TBL] [Abstract][Full Text] [Related]
13. Activation of the kynurenine pathway and increased production of the excitotoxin quinolinic acid following traumatic brain injury in humans.
Yan EB; Frugier T; Lim CK; Heng B; Sundaram G; Tan M; Rosenfeld JV; Walker DW; Guillemin GJ; Morganti-Kossmann MC
J Neuroinflammation; 2015 May; 12():110. PubMed ID: 26025142
[TBL] [Abstract][Full Text] [Related]
14. Indoleamine 2,3-dioxygenase 1 deficiency attenuates CCl4-induced fibrosis through Th17 cells down-regulation and tryptophan 2,3-dioxygenase compensation.
Zhong W; Gao L; Zhou Z; Lin H; Chen C; Huang P; Huang W; Zhou C; Huang S; Nie L; Liu Y; Chen Y; Zhou D; Lv Z
Oncotarget; 2017 Jun; 8(25):40486-40500. PubMed ID: 28465467
[TBL] [Abstract][Full Text] [Related]
15. Identification of selective inhibitors of indoleamine 2,3-dioxygenase 2.
Bakmiwewa SM; Fatokun AA; Tran A; Payne RJ; Hunt NH; Ball HJ
Bioorg Med Chem Lett; 2012 Dec; 22(24):7641-6. PubMed ID: 23122865
[TBL] [Abstract][Full Text] [Related]
16. Iron activates microglia and directly stimulates indoleamine-2,3-dioxygenase activity in the N171-82Q mouse model of Huntington's disease.
Donley DW; Realing M; Gigley JP; Fox JH
PLoS One; 2021; 16(5):e0250606. PubMed ID: 33989290
[TBL] [Abstract][Full Text] [Related]
17. L-tryptophan-kynurenine pathway metabolites regulate type I IFNs of acute viral myocarditis in mice.
Hoshi M; Matsumoto K; Ito H; Ohtaki H; Arioka Y; Osawa Y; Yamamoto Y; Matsunami H; Hara A; Seishima M; Saito K
J Immunol; 2012 Apr; 188(8):3980-7. PubMed ID: 22422885
[TBL] [Abstract][Full Text] [Related]
18. IDO and interferon-alpha-induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity.
Wichers MC; Koek GH; Robaeys G; Verkerk R; Scharpé S; Maes M
Mol Psychiatry; 2005 Jun; 10(6):538-44. PubMed ID: 15494706
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of the kynurenine pathway protects against reactive microglial-associated reductions in the complexity of primary cortical neurons.
O'Farrell K; Fagan E; Connor TJ; Harkin A
Eur J Pharmacol; 2017 Sep; 810():163-173. PubMed ID: 28688912
[TBL] [Abstract][Full Text] [Related]
20. Endogenous kynurenate controls the vulnerability of striatal neurons to quinolinate: Implications for Huntington's disease.
Sapko MT; Guidetti P; Yu P; Tagle DA; Pellicciari R; Schwarcz R
Exp Neurol; 2006 Jan; 197(1):31-40. PubMed ID: 16099455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
